^
    2years
    Tandem CAR-T cells targeting CLDN18.2 and NKG2DL for treatment of gastric cancer. (ASCO 2022)
    Our work construct a tandem CAR molecule targeting two tumor-associated antigens, NKG2DL and CLDN18.2, and found that Tan-CAR-T cells（KD-496）distinctly recognize the antigens and exhibited superior antitumor effect. KD-496 CAR-T cells potently respond to GC and more efficient tumor elimination than single CAR such as KD-025 and KD-182 CAR-T cells in PDX model with no obvious safety issue. The results support future clinical trial of KD-496 CAR in patients with GC, where the need for effective treatment is great.
    CAR T-Cell Therapy • IO biomarker
    |
    CLDN18 (Claudin 18) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CLDN8 (Claudin 8) • NKG2D (killer cell lectin like receptor K1)
    |
    CLDN18.2 expression
    |
    KD-025 CAR T-cells • KD-182